Drug Trial Radar · NCT01457417
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Jan 2012
Primary completion
Dec 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- Leap Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.
Conditions
- Multiple Myeloma
- Solid Tumors
- Non-Small Cell Lung Cancer
Interventions
DKN-01Drug
DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Total Adverse Events (AE)Time frame: Baseline to study completion (approximately 3 months)
- Summary of Patients With Adverse Events (AE)Time frame: Baseline to study completion (approximately 3 months)
- Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)Time frame: Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Scottsdale Healthcare
Scottsdale, Arizona
New York Oncology Hematology, P.C.
Albany, New York
Greenville Hospital System University Medical Center
Greenville, South Carolina
Texas Oncology - Baylor, Charles A. Sammonds Cancer Center
Dallas, Texas
Texas Oncology - Tyler
Tyler, Texas
Virginia Oncology Associated
Norfolk, Virginia
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia
Northwest Cancer Specialists, P.C.
Vancouver, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.